Actively Recruiting
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2025-07-11
60
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
CONDITIONS
Official Title
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects, age 18 years or older
- Histologically and/or cytologically confirmed advanced or measurable solid tumors
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of at least 3 months
- Willingness to provide written informed consent for the study
You will not qualify if you...
- Known uncontrolled or symptomatic central nervous system metastatic disease
- Subjects must have recovered to Grade 1 or baseline from adverse events caused by previous therapies (per NCI CTCAE v5.0)
- Inadequate organ or bone marrow function
- Pregnant or breastfeeding women
- Known allergies, hypersensitivity, or intolerance to HBT-708
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here